Sage Therapeutics, Inc.

NasdaqGM:SAGE Stock Report

Market Cap: US$543.6m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Sage Therapeutics Valuation

Is SAGE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of SAGE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate SAGE's fair value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate SAGE's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SAGE?

Key metric: As SAGE is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SAGE. This is calculated by dividing SAGE's market cap by their current revenue.
What is SAGE's PS Ratio?
PS Ratio7.7x
SalesUS$70.41m
Market CapUS$543.56m

Price to Sales Ratio vs Peers

How does SAGE's PS Ratio compare to its peers?

The above table shows the PS ratio for SAGE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average36.7x
CAPR Capricor Therapeutics
101.7x45.99%US$1.1b
ANAB AnaptysBio
7.7x19.74%US$1.3b
VSTM Verastem
35.2x44.23%US$470.8m
KROS Keros Therapeutics
2.2x-23.16%US$545.6m
SAGE Sage Therapeutics
7.7x25.97%US$543.6m

Price-To-Sales vs Peers: SAGE is good value based on its Price-To-Sales Ratio (7.7x) compared to the peer average (16.1x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does SAGE's PS Ratio compare vs other companies in the US Biotechs Industry?

122 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
2.6x-1.15%US$26.39b
BMRN BioMarin Pharmaceutical
3.5x6.66%US$10.86b
PTCT PTC Therapeutics
3.4x1.30%US$6.06b
ALKS Alkermes
3.7x8.74%US$5.60b
SAGE 7.7xIndustry Avg. 11.6xNo. of Companies122PS01632486480+
122 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: SAGE is good value based on its Price-To-Sales Ratio (7.7x) compared to the US Biotechs industry average (8.6x).

Price to Sales Ratio vs Fair Ratio

What is SAGE's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SAGE PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio7.7x
Fair PS Ratio0.4x

Price-To-Sales vs Fair Ratio: SAGE is expensive based on its Price-To-Sales Ratio (7.7x) compared to the estimated Fair Price-To-Sales Ratio (0.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SAGE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$8.73
0%
14.57%US$12.00US$6.00n/a12
Jan ’27n/a
US$8.73
0%
14.57%US$12.00US$6.00n/a12
Dec ’26n/a
US$8.73
0%
14.57%US$12.00US$6.00n/a12
Nov ’26n/a
US$8.73
0%
14.57%US$12.00US$6.00n/a12
Oct ’26n/a
US$8.73
0%
14.57%US$12.00US$6.00n/a12
Sep ’26n/a
US$8.73
0%
14.57%US$12.00US$6.00n/a12
Aug ’26US$8.68
US$8.73
+0.52%
14.57%US$12.00US$6.00n/a12
Jul ’26US$9.08
US$8.90
-2.03%
15.29%US$12.00US$6.00n/a16
Jun ’26US$6.46
US$8.21
+27.13%
24.50%US$12.00US$5.00n/a18
May ’26US$7.48
US$8.10
+8.31%
23.55%US$12.00US$5.00n/a18
Apr ’26US$7.86
US$8.05
+2.37%
24.27%US$12.00US$5.00n/a18
Mar ’26US$7.30
US$8.23
+12.68%
22.62%US$12.00US$5.00n/a17
Feb ’26US$7.25
US$8.64
+19.13%
27.19%US$14.00US$5.00n/a17
Jan ’26US$5.43
US$9.00
+65.75%
57.17%US$26.00US$4.00n/a17
Dec ’25US$5.47
US$9.47
+73.14%
53.12%US$26.00US$4.00n/a17
Nov ’25US$6.05
US$10.17
+68.04%
43.90%US$26.00US$4.00n/a18
Oct ’25US$6.96
US$14.33
+105.94%
68.83%US$52.00US$9.00n/a18
Sep ’25US$8.43
US$14.33
+70.03%
68.83%US$52.00US$9.00n/a18
Aug ’25US$9.76
US$14.89
+52.61%
64.47%US$52.00US$8.00US$8.6819
Jul ’25US$11.03
US$20.37
+84.66%
60.39%US$70.00US$8.00US$9.0819
Jun ’25US$11.11
US$21.11
+89.97%
58.54%US$70.00US$8.00US$6.4619
May ’25US$13.28
US$22.17
+66.92%
54.95%US$70.00US$14.00US$7.4818
Apr ’25US$17.90
US$27.42
+53.19%
39.30%US$70.00US$18.00US$7.8619
Mar ’25US$21.86
US$27.16
+24.24%
39.75%US$70.00US$18.00US$7.3019
Feb ’25US$26.00
US$26.79
+3.04%
48.15%US$79.00US$20.00US$7.2519
US$8.73
Fair Value
0.5% undervalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/08/01 03:26
End of Day Share Price 2025/07/30 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sage Therapeutics, Inc. is covered by 9 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Esther Lannie HongBerenberg
null nullBMO Capital Markets Equity Research
Gary NachmanBMO Capital Markets Equity Research